BIOM30001 Lecture Notes - Lecture 33: Suvorexant, Merck & Co., Cyp3A4
Document Summary
Merck said the drug worked better than a placebo at measurements including total sleep time, time to falling asleep, and continuous sleep after one month and three months of treatment. The company said patients reported better results on suvorexant compared with placebo, and their sleeping habits also were measured electronically. Suvorexant is a new type of insomnia drug designed to minimize morning grogginess. Blocks oxr and blocks hyperactivity of orexin stimulating receptors. It is one of merck"s major drug candidates. The company plans to file for u. s. marketing approval this year, and it is one of six planned product filings for merck in 2012 and. The two trials involved more than 2,000 patients who had insomnia that was not caused by another medical problem. The most common side effects of suvorexant were tiredness and headache. Shares of merck rose 26 cents to . 69 in morning trading. Fda scraps merck"s high-dose sleep drug, demands weaker version.
